TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06915025: Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopi

Sponsor: Imunon · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 500 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$20,993,280

Rescue Site Savings

+$13,842,444

Unlock Full NCT06915025 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06915025 Rescue Dossier →